USD
Increase targetBefore 15.98%Target 16%
Cash allocation. No separate rationale was supplied.
Strategy decision
Loading the recorded decision…
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Sep 18, 2026, 8:19 AM EDT
Using this strategy in your portfolio? Open the Builder to review its source targets. Review your saved portfolio →
The decision
I retain a 12-stock, equal-weight defensive book and 16% cash. This reduces single-name variance while balancing utilities, healthcare, and staples. The selection favors relatively contained or positive 20-session movement, dividends where supplied, and reasonable valuation evidence where available. I replace BG with DUK to deepen regulated-utility exposure and remove the strongest recent advance from the prior book.
Targets & reasoning
Before is the portfolio weight captured at decision time. Target is the requested allocation—not confirmation of a completed trade. These are simulated strategy weights, not personalized allocations.
Cash allocation. No separate rationale was supplied.
I expect AES to contribute measured income and modest price resilience because its 4.74% trailing dividend yield and 7.35 P/E provide valuation support, while its 20-session return is a contained positive 1.02%. I am wrong if the positive trend reverses into a persistent downside break.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: quarters
I expect AWK to damp portfolio variance through its water-utility exposure, supported by a 2.49% trailing dividend yield and nearly flat 20-session return of -0.34%. Its price is also close to the 20-session average. I am wrong if the near-flat pattern becomes sustained weakness.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect CI to compound with limited recent trend risk because its 10.94 P/E is the lowest supplied healthcare valuation and its 20-session return is near flat at -0.52%. The 2.24% trailing dividend yield adds carry. I exit if earnings valuation support weakens alongside a persistent drawdown.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: months
I expect DUK to improve the portfolio's defensive income balance through electric-utility exposure, a 3.61% trailing dividend yield, and a 17.46 P/E. The recent 4.09% decline is a controlled-sized entry rather than a concentration bet. I am wrong if that decline persists materially beyond its recent range.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: quarters
I expect ED to provide a low-drama utility sleeve because its 3.28% trailing dividend yield and 14.53 P/E pair with a modest 20-session return of -0.85%. The close is nearly equal to its 20-session average. I exit if price dispersion expands into a sustained decline.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect ELV to add healthcare return potential without relying on a depressed trend: its 20-session return is 3.97% and its close exceeds the 20-session average. A 14.93 P/E supplies a reasonable valuation anchor. I am wrong if this positive trend fails and valuation support no longer contains downside.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
I expect GILD to offer steadier healthcare participation because it has a 2.15% trailing dividend yield and a controlled positive 20-session return of 2.23%. Its close remains above the 20-session average. I exit if this relative strength reverses into sustained below-average trading.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
I expect KDP to contribute consumer-staples stability as its 20-session return is a restrained positive 1.19%, limiting evidence of sharp current movement. Its 2.93% trailing dividend yield provides carry. I am wrong if the close remains below its 20-session average and the mild positive trend deteriorates.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
I expect KO to remain a measured staples holding because its 2.38% trailing dividend yield supports total return and its 20-session decline of 2.53% is less severe than several alternatives. I am wrong if the decline broadens persistently below the 20-session average.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect MDT to provide diversified healthcare exposure with dividend carry because its trailing yield is 3.07% and the 20-session return is a contained -1.44%. The close remains slightly above its 20-session average. I exit if price loses that average and the drawdown persists.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect PG to compound quietly in the staples sleeve because its 20-session return is 2.20% and the close is above its 20-session average. Its 2.91% trailing dividend yield adds a stable return component. I am wrong if the positive, low-amplitude pattern reverses into persistent weakness.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect PM to add income-supported staples diversification because its 3.09% trailing dividend yield accompanies an almost flat 20-session return of 0.29%. The close is slightly above its 20-session average. I exit if this calm trading pattern shifts into a sustained decline below that average.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
Exit BG because its 20-session return of 4.66% is the strongest advance in the current book, adding less mean-reverting defensive evidence than DUK's regulated-utility income profile. Its 27.81 P/E is also elevated relative to several retained holdings.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: weeks
Portfolio checks
The complete proposal passed the versioned universe, cash, concentration, and posture constraints without platform modification.
These checks cover portfolio constraints. A separate portfolio-level investment-risk assessment was not supplied in this field. Review the holding explanations for recorded thesis and exit conditions.
Ongoing review
Monitor owned and favored symbols against the current mandate and rebalance through platform risk controls. Monitor for mandate drift. Rebalance through platform risk controls when targets shift materially.
This is the platform's monitoring description for the strategy, not a forecast from this decision.
Decision ≠ execution
This view shows one representative order and fill, not every leg of a rebalance. A recorded fill below does not confirm that all target weights were reached. Open the strategy portfolio to inspect current holdings.
Evidence behind the explanation
The explanations above preserve the reasoning recorded with this decision. The record details below show processing and execution history. They do not provide source documents for the financial claims in the explanations.
This checks record linkage, not investment quality or completion of every trade.
These identify processing inputs and validation steps. They are not linked research sources.
Low Volatility Allocator cycle started by scheduled.
Low Volatility Allocator produced a canonical target-weight decision.
Created buy proposal for DUK-USD.
Risk engine approved proposal 01M2T7K4E2JY1X6Y4N90HF6MW0.
Queued buy order for DUK-USD for MOO execution.
Low Volatility Allocator cycle completed with status pending_fill.
Low Volatility Allocator valuation snapshot recorded for agent_cycle_run 01M2T7H6KNJ2XW2M10D1JCNCRT.
Assumed MOO buy fill for DUK-USD at the verified session open.
Simulated buy fill for DUK-USD at the verified MOO session open.
Recorded balanced ledger entries for assumed MOO fill.